Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Diethylstilbestrol (DES) is an oral small-molecule synthetic estrogen tablet developed by Eli Lilly. The drug's mechanism of action, specific indications, and current clinical applications are not specified in available data. This product is currently in pre-launch phase as an NDA (New Drug Application).
Pre-Launch
Pre-launch stage suggests active commercial team building and market preparation activities at Eli Lilly.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
A Study of Pharmacodynamic and Genetic Parameters of Abira-DES Study Participants (NCT02217566) - Participants With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Following Unresponsive Treatment With Diethylstilbestrol
Started Mar 2020
42 enrolled
Metastatic Castration-resistant Prostate Cancer
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
Started Sep 2014
46 enrolled
Prostatic Neoplasms
Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Cancer
Started Dec 2002
30 enrolled
Prostate Cancer
Career Relevance
Worked on DIETHYLSTILBESTROL at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.